Five considerations when scaling up mAbs in partnership with a CDMO
A successful monoclonal antibody could undergo scale-up several times across the span of its commercial life, each stage presenting new complexities during sterile fill-finish. As more sponsors turn to CDMOs to handle this crucial step, what do companies need to know to avoid delays, bottlenecks, compliance hurdles, and more?
